Key Takeaways ISRG Q2 top line beat estimates but shares fell 7% on tariff impact, cost inflation, and margin pressure.ISRG flagged CapEx risks, shifting procedure mix, and rising expenses as near-term challenges.ISRG sees growth from da Vinci 5 adoption, new approvals, and long-term telesurgery potential.Intuitive Surgical (ISRG) posted second-quarter fiscal 2025 results on July 22. It delivered a solid top-line beat and healthy procedure growth, but shares have lost more than 7% since the release. While o ...